Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.

BMC medicine - 26 Jul 2022

Ricardo-Silgado Maria L, Singh Sneha, Cifuentes Lizeth, Decker Paul A, Gonzalez-Izundegui Daniel, Moyer Ann M, Hurtado Maria D, Camilleri Michael, Bielinski Suzette J, Acosta Andres

Abstract excerpt

BACKGROUND: Prescription medications such as selective serotonin reuptake inhibitors (SSRIs), commonly used to treat depression, are associated with weight gain. The role of pharmacogenomics in predicting SSRI-induced weight gain is unclear. METHODS: In this retrospective cohort study from participants in the Mayo Clinic RIGHT study who were prescribed citalopram, paroxetine, sertraline, or fluoxetine, our aim...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Citalopram
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 CYP2D6

Share to Fluoxetine

Share to Paroxetine

Share to Selective Serotonin Reuptake Inhibitors

Share to Weight Gain

Source

Open in PubMed Open full text

Identifiers

PMID: 35879764
DOI: 10.1186/s12916-022-02433-x
PMCID: PMC9317126

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.PMID 35879764Read ↗

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression StudySemantic proximity Read ↗

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK BiobankSemantic proximity Read ↗

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.Semantic proximity Read ↗

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studiesSemantic proximity Read ↗

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputationSemantic proximity Read ↗

Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis.Semantic proximity Read ↗

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.Semantic proximity Read ↗

CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability.Semantic proximity Read ↗

Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.Semantic proximity Read ↗

Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Semantic proximity Read ↗

Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities.Semantic proximity Read ↗

CYP2C19 loss-of-function alleles are not associated with higher prevalence of gastrointestinal bleeds in those who have been prescribed antidepressants: Analysis in a British-South Asian cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.